Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen

Journal of Thoracic Oncology

Volumn 4, Issue 6, 2009, Pages 689-696

  Salmon, Stuart ^a   Chen, Heidi ^b   Chen, Shuo ^b   Herbst, Roy ^c   Tsao, Anne ^c   Tran, Hai ^c   Sandler, Alan ^b   Billheimer, Dean ^d   Shyr, Yu ^b   Lee, Ju Whei ^e   Massion, Pierre ^b   Brahmer, Julie ^f   Schiller, Joan ^g   Carbone, David ^b   Dang, Thao P ^b,h  

^a Carolinas Hematology Oncology Associates   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f JOHNS HOPKINS HOSPITAL   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h Department of Medicine and Cancer Biology ^*  (United States)

Author keywords

Biomarkers; Lung cancer; Proteomics

Indexed keywords

BEVACIZUMAB; ERLOTINIB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ACCURACY; ADULT; AGED; ALGORITHM; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POPULATION; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEOMICS; RECURRENT CANCER; REFRACTORY PERIOD; RELIABILITY; BLOOD; CASE CONTROL STUDY; CLASSIFICATION; COMPARATIVE STUDY; LUNG TUMOR; MASS SPECTROMETRY; MIDDLE AGED; PLEURA EFFUSION; PROGNOSIS; REPRODUCIBILITY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; QUINAZOLINES; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 67849122650     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181a526b3     Document Type: Article

References (12)

1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353: 123-132. (Pubitemid 41058344)
2. Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 2005;23:3243-3256. (Pubitemid 46211349)
3. Sandler A, Gray R, Perry MC. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550. (Pubitemid 44917502)
4. Herbst RS, Johnson DH, Mininberg E. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-smallcell lung cancer. J Clin Oncol 2005;23:2544-2555.
5. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-smallcell lung cancer. J Clin Oncol 2007;25:587-595. (Pubitemid 350002967)
6. Zhu CQ, da Cunha Santos G, Ding K. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol 2008;26: 4268-4275.
7. Stinchcombe TE, Socinski MA. Bevacizumab in the treatment of nonsmall- cell lung cancer. Oncogene 2007;26:3691-3698. (Pubitemid 46842701)
8. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004;96:353-356.
9. Taguchi F, Solomon B, Gregorc V. Mass spectrometry to classify nonsmall- cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 2007;99:838-846.
10. Yildiz PB, Shyr Y, Rahman JS. Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol 2007;2:893-901. (Pubitemid 47511591)
11. Petricoin EF, Ardekani AM, Hitt BA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-577. (Pubitemid 34178440)
12. Baggerly KA, Morris JS, Edmonson SR, Coombes KR. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 2005;97:307-309.